2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2844 Comparison of real-world outcomes in accelerated/blast Phase myeloproliferative neoplasms (MPNs) with acute myeloid leukemia, myelodysplasia-related (AML-MR) in patients (pts) 60 years (yrs) and older: A MARROW consortium analysis

Michael Jamie Hochman, MD, Jhonsley Frederic, MD2, Deedra Nicolet, MS3, Onyee Chan, MD4, Justice Ameyi, M.S.5, Krzysztof Mrózek, MD, PhD6, Michael Walker7, Preem Geeta Torlapati, MD, MPH8, Alexander Joseph Ambinder, MD, MPH9, Utsav Joshi, MD10, Rami Komrokji, MD11, Najla Al Ali, MS12, Jesus D Gonzalez-Lugo, MD13, Tara L. Lin, MD14, Joshua F. Zeidner, MD15, Daniel T Peters, MD16, Roberto Garcia, MD17, Charles Foucar, MD18, Kieran Sahasrabudhe, MD19, Bianca Barredo, BS20, Lauren G. Banaszak, MD21, Stephanie Begley, MS22, Brittany Knick Ragon, MD23, Christine M. McMahon, MD24, Alice Scott Mims, MD25, Ann-Kathrin Eisfeld, MD26, Anthony Michael Hunter, MD27
1 Emory Winship Cancer Institute, Atlanta, Georgia, United States
2 Morehouse School of Medicine, Atlanta, Georgia, United States
3 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
6 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
7 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
8 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
9 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 The University of Kansas Cancer Center Kansas City, Kansas City, Missouri, United States
14 The University of Kansas Cancer Center Kansas City, Kansas City, Missouri, United States
15 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
16 Georgia Cancer Center, Augusta, Georgia, United States
17 University of New Mexico, Albuquerque, New Mexico, United States
18 University of New Mexico, Albuquerque, New Mexico, United States
19 University of Wisconsin, Madison, Wisconsin, United States
20 University of Wisconsin, Madison, Wisconsin, United States
21 University of Wisconsin, Madison, Wisconsin, United States
22 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
23 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
24 University of Colorado, Aurora, Colorado, United States
25 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
26 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
27 Emory Winship Cancer Institute, Atlanta, Georgia, United States

Introduction: MPNs are chronic clonal myeloid neoplasms with underlying biology typically driven by mutations in the JAK-STAT pathway: JAK2, CALR, and MPL. Though the prognosis of most pts with MPNs is generally favorable, progression to accelerated or blast phase disease (MPN-A/BP; defined by blasts 10-19% and ≥20%, respectively, in blood or bone marrow [BM]) is associated with dismal prognosis. Lower-intensity therapy (LIT) using venetoclax plus hypomethylating agents (VEN/HMA) has been pivotal in the treatment of older and frail pts with AML, with increasing use observed in MPN-BP. Yet, MPN-A/BP appears to have a prognosis disproportionately worse than AML-MR. Therefore, we aimed to compare outcomes among pts with MPN-A/BP and AML-MR.

Methods: We identified pts with MPN-A/BP from 4 institutions within the Myeloid Malignancy Association for Retrospective Research Outcomes Working Group (MARROW). Initial chronic phase MPN was diagnosed by WHO criteria or presumed based on the presence of MPN driver mutations with appropriate preceding blood count abnormalities. A cohort of pts with AML-MR was used as a comparator. Therapy-related AML was excluded. Baseline demographic and disease characteristics were described. Wilcoxon rank-sum and Fisher’s exact tests were used to compare groups. Kaplan-Meier curves were generated to evaluate overall survival (OS) and disease-free survival (DFS), which were compared using log rank test. Univariable (UVA) and multivariable analyses (MVA) were used to evaluate associations between OS, DFS, and complete remission (CR) and the following covariates (quantitative unless otherwise noted): age, sex, race, performance status, baseline blood counts, BM blasts, somatic mutations, disease type (MPN-A/BP vs AML-MR), treatment (intensive chemotherapy [IC] vs VEN/HMA), European LeukemiaNet (ELN) 2024 risk group, and allogeneic hematopoietic cell transplant (allo-HCT).

Results: A total of 146 pts with MPN-A/BP were identified, the majority of whom were aged ≥60 yrs (86.3%); 74 received LIT, most commonly VEN/HMA (n=39). The AML-MR cohort included 227 pts. Because all pts in this cohort were aged ≥60 yrs, we compared them with MPN-A/BP pts in the same age range in subsequent analyses (n=126). Whereas older pts with MPN-A/BP mostly received LIT (71%), this was the minority of AML-MR pts (n=89, all of whom received VEN/HMA). More pts with AML-MR underwent allo-HCT than pts with MPN-A/BP (27% vs 17%; P=0.05). ELN 2024 risk was similar between the pt groups: 68% had favorable risk in MPN-A/BP and 69% in AML-MR; 11% were intermediate risk and 21% were adverse risk in both groups.

Treatment of MPN-A/BP with IC resulted in longer OS (median, 1.4 yrs) than LIT (median, 0.6 yrs, P=0.004), though few IC-treated pts and selection bias likely contributed. In MVA including AML-MR and MPN-A/BP pts, treatment-type was not predictive of OS or DFS, though CR was superior with IC (odds ratio [OR] 1.77, 95% confidence interval [CI] 1.02-3.07, P=0.04).

Among pts receiving VEN/HMA, rate of CR was 53% in AML-MR pts and 42% in MPN-A/BP pts (P=0.25). Pts with AML-MR demonstrated superior OS compared to MPN-A/BP pts, with 3-year rate of 28% for AML-MR versus 12% for MPN-A/BP (P=0.02). DFS rate at 3 yrs was also higher for AML-MR than for MPN-A/BP (28% vs 12%), though not statistically significant (P=0.10). Disease type (MPN-A/BP vs AML-MR) was significantly associated with DFS in both UVA and MVA (hazard ratio [HR] 4.71, 95% CI 2.12-10.47, P < 0.001). UVA demonstrated worse OS with MPN-A/BP diagnosis compared to AML-MR (HR 1.68, 95% CI 1.08-2.61, P=0.02); this finding was retained in MVA (HR 1.70, 95% CI 1.00-2.92, P=0.05). ELN 2024 group was not included in this model due to the small number of intermediate risk pts, but adverse risk was captured by incorporation of TP53 mutation status (highly predictive of OS in MVA). Allo-HCT was a strong predictor of OS in MVA (HR 0.12, 95% CI 0.04-0.34, P <0.001), though only 16% of VEN/HMA-treated MPN-A/BP pts ultimately received allo-HCT.

Conclusion: Older pts with MPN-A/BP demonstrate disproportionately worse outcomes than those with AML-MR despite similar ELN 2024 risk distribution. Caution must be taken in interpreting these data given the retrospective nature of this study. However, these findings support distinct disease biology in MPN-A/BP, indicating that prospective clinical trials in MPN-A/BP are essential to improve outcomes in this high-risk, understudied group.

Michael Jamie Hochman, MD: Doximity - Stock (publicly traded); Blueprint Medicines - Honoraria; Astellas Pharma - Honoraria; Rigel Pharmaceuticals - Honoraria; Daiichi-Sankyo - Honoraria; Taiho Oncology - Research Funding; Blueprint Medicines - Research Funding; Daiichi-Sankyo - Research Funding; Geron Corporation - Research Funding; Johnson & Johnson - Consultancy (Includes expert testimony)